Navigation

Determining local service levels for biologic drugs for the treatment of inflammatory disease

Benchmarks for a standard population

Available data suggest that the indicative benchmark for adults aged 18 years or older needing biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology is 0.19% or 190 per 100,000 adult population per year.

For a standard population of 100,000, around 80% or 80,000 people would be aged 18 or older. The average number of people needing biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology is around 150 per year (which equates to 0.19% of the population aged 18 years or older).

For an average practice with a list size of 10,000, around 80% or 8,000 people would be aged 18 years or older. The average number of people with inflammatory disease in rheumatology, dermatology and gastroenterology needing biologic drugs is 15 per year (which equates to 0.19% of the population aged 18 years or older).

Owing to the small number of children who may be eligible for biologic drugs, separate benchmarks for juvenile idiopathic arthritis and children with Crohn's disease are provided later in the guide.

Examine the assumptions used in estimating these figures.

Commissioning biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology is likely to fall under the programme budgeting categories 213X (problems of the gastro intestinal system), 214X (problems of the skin) and 215X (problems of the musculoskeletal system).

Use the biologic drugs commissioning and benchmarking tool to determine the level of service that might be needed locally and to calculate the cost of commissioning the service using the indicative benchmark and/or your own local data. The commissioning and benchmarking tool contains a sensitivity analysis for each condition which provides a range to reflect the uncertainties within published literature, audit and clinical opinion on the rapidly changing uptake of biologic drugs for inflammatory disease.

Further information

Sources of further information to help you in assessing local health needs and reducing health inequalities include:

This page was last updated: 02 March 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.